The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK

被引：0

作者：

Elnaggar, Mohamed ^{[1
]}

Mansinho, Joana Nunes ^{[2
]}

Malkin, Samuel J. P. ^{[3
]}

Whitaker, Joseph ^{[2
]}

Hunt, Barnaby ^{[3
]}

Glah, Divina ^{[2
]}

Maclellan, Martina ^{[2
]}

Ali, Samina ^{[4
]}

机构：

[1] Univ Hosp Morecambe Bay NHS Fdn Trust, Endocrinol Diabet & Metab Dept, Kendal, England

[2] Novo Nordisk Ltd, Gatwick, England

[3] Ossian Hlth Econ & Commun GmbH, Baumleingasse 20, CH-4051 Basel, Switzerland

[4] NHS Greater Glasgow & Clyde, Glasgow, Scotland

来源：

DIABETES THERAPY | 2025年

关键词：

Cost; Cost-effectiveness; Liraglutide; Oral semaglutide; UK; TYPE-2; DIABETES-MELLITUS; CARDIOVASCULAR OUTCOMES; COMPLICATIONS; HYPERGLYCEMIA; HYPOGLYCEMIA; INDIVIDUALS; MANAGEMENT; SIMULATE; EVENTS; PEOPLE;

D O I：

10.1007/s13300-025-01691-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

IntroductionGlucagon-like peptide-1 (GLP-1) receptor agonists represent efficacious therapies for treating type 2 diabetes. Oral semaglutide is the only orally administered GLP-1 receptor agonist currently available and has been associated with reductions in glycated hemoglobin and body weight versus once-daily injectable liraglutide after 52 weeks in the PIONEER 4 clinical trial. As lower-cost liraglutide formulations have recently been developed, the present analysis evaluated the long-term cost-effectiveness of oral semaglutide 14 mg versus liraglutide 1.8 mg at lower acquisition costs in the UK.MethodsThe published and validated PRIME Type 2 Diabetes Model was used to project clinical and cost outcomes over patient lifetimes. Baseline cohort characteristics, as well as treatment-specific changes in physiological parameters and hypoglycemia rates, were sourced from PIONEER 4. Patients were modeled to receive oral semaglutide or liraglutide until HbA1c exceeded 8.0% (64 mmol/mol), after which treatment was intensified to basal insulin. Annual disutilities associated with treatment administration were applied to capture the differential impact of a once-daily oral versus once-daily injectable medication on quality of life. Costs, expressed in 2022 pounds sterling (GBP), were calculated from a National Health Service (NHS) perspective. The acquisition cost of liraglutide was reduced by up to 50% at increments of 5% across a range of scenarios.ResultsOral semaglutide was associated with improved quality-adjusted life expectancy of 0.18 quality-adjusted life years versus liraglutide 1.8 mg due to a reduced incidence of diabetes-related complications and a reduced treatment-administration burden. Direct, per-person complication costs were estimated to be GBP 187 lower with oral semaglutide. Oral semaglutide remained dominant or cost-effective in the majority of scenarios, even with liraglutide price reductions of 50% applied.ConclusionsOral semaglutide 14 mg was projected to be cost-effective versus lower-cost liraglutide 1.8 mg in the UK.

引用

页码：613 / 628

页数：16

共 56 条

[1] Davies M.J., Aroda V.R., Collins B.S., Et al., Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), Diabetes Care, 45, 11, pp. 2753-2786, (2022)
[2] Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, pp. 837-853, (1998)
[3] Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes, N Engl J Med, 358, pp. 2560-2572, (2008)
[4] Ismail-Beigi F., Craven T., Banerji M.A., Basile J., Calles J., Cohen R.M., Cuddihy R., Cushman W.C., Genuth S., Grimm R.H., Hamilton B.P., Hoogwerf B., Karl D., Katz L., Krikorian A., O'Connor P., Pop-Busui R., Schubart U., Simmons D., Taylor H., Thomas A., Weiss D., Hramiak I., Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial, Lancet, 376, pp. 419-430, (2010)
[5] Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, BMJ, 317, 7160, pp. 703-713, (1998)
[6] Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis, Lancet, 371, 9607, pp. 117-125, (2008)
[7] Gaede P., Lund-Andersen H., Parving H.H., Pedersen O., Effect of a multifactorial intervention on mortality in type 2 diabetes, N Engl J Med, 358, pp. 580-591, (2008)
[8] Diabetes UK. How many people in the UK have diabetes? 2022. Available at
[9] Hex N., MacDonald R., Pocock J., Et al., Estimation of the direct health and indirect societal costs of diabetes in the UK using a cost of illness model, Diabet Med, 41, (2024)
[10] Trujillo J.M., Nuffer W., Smith B.A., GLP-1 receptor agonists: an updated review of head-to-head clinical studies, Ther Adv Endocrinol Metab, 12, pp. 1-15, (2021)

← 1 2 3 4 5 6 →